JENKEM stated on the interactive platform on September 2nd that the company has initially formed and is continuously strengthening its computational biology team to actively explore the optimization of existing R&D processes through AI, particularly in key areas such as drug structure design and molecular screening. The goal is to achieve a more scientific and efficient decision-making process, thereby promoting the R&D progress of polyethylene glycol material innovation applications. As of now, the company has not yet achieved significant R&D results through AI, and it will not have a major impact on the company's performance in the short term. However, the company recognizes the enormous potential of AI technology in enhancing R&D efficiency and reducing R&D costs